Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). (Q37692798)
scientific article published on September 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | No label defined |
||
| English | Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). |
scientific article published on September 2009 |
Statements
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R) (English)
Jerzy Holowiecki
Saengsuree Jootar
Jorge Cortes
Ricardo Pasquini
Timothy Hughes
Eric Bleickardt
Neil P Shah
Hagop Kantarjian
1 September 2009
1 reference
1 reference
1 reference